Amicus blueprints growth plans for Philly-based gene therapy group; Cash-strapped Compugen restructures, cuts 35 staffers
→ As Roche puts down its foot in Philadelphia as the base for its budding gene therapy operations built around new subsidiary Spark Therapeutics, Amicus $FOLD is blueprinting its own gene therapy group in the city.
Amicus first made its foray into gene therapy via the acquisition of Celenex, which came with 10 programs in neurologic lysosomal storage disorders from Batten disease to Tay Sachs. Shortly thereafter, the rare disease specialist teamed up with James Wilson at the University of Pennsylvania to advance gene therapy treatments for Pompe disease, Fabry disease, CDKL5 deficiency and one other undisclosed rare metabolic disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
